Rigel Pharmaceuticals, Inc. (RIGL) Earnings History
Profitable27 years of earnings data (1999–2025) · Positive TTM net income
Loading earnings history...
Rigel Pharmaceuticals, Inc. (RIGL) Earnings Overview
As of September 22, 2026, Rigel Pharmaceuticals, Inc. (RIGL) reported trailing twelve-month net income of $322M, reflecting +1867.7% year-over-year growth. The company earned $16.45 per diluted share over the past four quarters, with a net profit margin of 124.7%.
Looking at the long-term picture, RIGL's historical earnings data spans multiple years. The company achieved its highest annual net income of $367M in fiscal 2025, representing a new all-time high.
Rigel Pharmaceuticals, Inc. maintains industry-leading profitability with a gross margin of 93.3%, operating margin of 42.6%, and net margin of 124.7%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including PRTA (-$44M net income, -2520.6% margin), FOLD (-$27M net income, -4.3% margin), RARE (-$586M net income, -85.4% margin), RIGL has outperformed on profitability metrics. Compare RIGL vs PRTA →
RIGL Earnings vs Peers
Earnings metrics vs comparable public companies
RIGL Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $367M | +1999.1% | $125M | $19.48 | 124.7% | 42.6% |
| 2024 | $17M | +169.7% | $24M | $0.99 | 9.8% | 13.5% |
| 2023 | -$25M | +57.2% | -$20M | $-1.44 | -21.5% | -17.5% |
| 2022 | -$59M | -227.0% | -$56M | $-3.40 | -48.7% | -46.2% |
| 2021 | -$18M | +39.8% | -$12M | $-1.10 | -12.0% | -8.4% |
| 2020 | -$30M | +55.3% | -$29M | $-1.80 | -27.4% | -26.7% |
| 2019 | -$67M | +5.6% | -$69M | $-4.00 | -112.2% | -116.5% |
| 2018 | -$70M | +9.6% | -$73M | $-4.40 | -158.3% | -163.3% |
| 2017 | -$78M | -12.7% | -$80M | $-6.17 | -1739.3% | -1775.6% |
| 2016 | -$69M | -34.5% | -$70M | $-7.33 | -339.6% | -342.2% |
| 2015 | -$51M | +43.4% | -$52M | $-5.82 | -178.1% | -179.1% |
| 2014 | -$91M | -2.1% | -$91M | $-10.37 | -1101.9% | -1106.0% |
| 2013 | -$89M | +9.9% | -$89M | $-10.20 | -1245.1% | -1251.3% |
| 2012 | -$99M | -15.0% | -$99M | $-6.14 | -4392.9% | -4416.8% |
| 2011 | -$86M | -326.9% | -$86M | $-3.67 | -1810.0% | -1818.3% |
| 2010 | $38M | +134.0% | $35M | $0.72 | 30.3% | 28.3% |
| 2009 | -$112M | +15.7% | -$112M | $-2.73 | -14872.9% | -14938.3% |
| 2008 | -$132M | -78.2% | -$137M | $-3.67 | - | - |
| 2007 | -$74M | -97.3% | -$80M | $-2.57 | -589.5% | -631.2% |
| 2006 | -$38M | +16.8% | -$43M | $-1.51 | -112.4% | -128.6% |
| 2005 | -$45M | +19.6% | -$48M | $-2.07 | -273.8% | -290.0% |
| 2004 | -$56M | -36.6% | -$57M | $-3.12 | -1188.6% | -1201.5% |
| 2003 | -$41M | -11.3% | -$41M | $-3.62 | -372.7% | -369.3% |
| 2002 | -$37M | -55.6% | -$37M | $-7.30 | -234.5% | -234.5% |
| 2001 | -$24M | +6.1% | -$25M | $-5.75 | -155.6% | -163.1% |
| 2000 | -$25M | -105.1% | -$26M | $-31.43 | -191.9% | -193.0% |
| 1999 | -$12M | - | -$12M | $-355.49 | -137.6% | -134.5% |
Download Data
Export RIGL earnings history in CSV or JSON format
Free sign-in required to download data
RIGL Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RIGL — Frequently Asked Questions
Quick answers to the most common questions about buying RIGL stock.
What is RIGL earnings per share (EPS)?
RIGL trailing twelve-month (TTM) diluted EPS is $16.45, reflecting +1867.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1999 to 2025 is available in the table on this page.
What is Rigel Pharmaceuticals, Inc.'s net income?
Rigel Pharmaceuticals, Inc. (RIGL) trailing twelve-month net income is $322M as of 2025. Earnings grew +1867.7% year-over-year. Rigel Pharmaceuticals, Inc. has been profitable for 2 consecutive years.
Is RIGL profitable?
Yes, RIGL is profitable with a TTM net income of $322M and a net profit margin of +124.7%. Rigel Pharmaceuticals, Inc. has generated profits for 2 consecutive years.
What is RIGL's earnings growth rate?
RIGL compound annual EPS growth rates (CAGR): 1-Year: +1867.7%, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1999 to 2025.
What are RIGL's profit margins?
Rigel Pharmaceuticals, Inc. net profit margin is +124.7%, operating margin is +42.6%, and gross margin is +93.3%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +185.9%.
Is RIGL growing earnings?
Yes, RIGL earnings are accelerating — EPS growth of +1867.7% exceeds the 5-year CAGR of N/A. TTM net income reached $322M. Earnings momentum is strengthening.
What was RIGL's best earnings year?
Rigel Pharmaceuticals, Inc.'s highest annual net income on record is $367M, achieved in fiscal year 2025. Earnings history on this page spans 1999 to 2025 and includes all annual and quarterly figures.
What were RIGL's earnings last quarter?
RIGL's most recent reported quarter was Q2 2026. Net income was $17M with diluted EPS of $0.88. For a full breakdown of all quarters, see the quarterly earnings table on this page.